Journals / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 4

Intravitreal Anti-VEGF Drug Injections in Vitrectomized Eyes

Vitrektomize Gözlerde İntravitreal Anti-VEGF İlaç Enjeksiyonları

Pages
307–313
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to discuss effects of vitrectomy on pharmacokinetics of anti-VEGF agents and clinical outcomes in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is currently the most commonly performed procedure in the fi eld of retina.
📊
Key Findings & Data:Generally, drug clearance has been assumed to increase and drug effectiveness decrease in vitrectomized eyes.
💡
Conclusion & Impact:We aimed to discuss effects of vitrectomy on pharmacokinetics of anti-VEGF agents and clinical outcomes in this review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is currently the most commonly performed procedure in the fi eld of retina. In eyes undergoing anti-VEGF treatment, clinicians are frequently challenged with conditions necessitating pars plana vitre- ctomy. However, for many patients, the chronic and recurrent nature of posterior segment disease necessitates continued intravitreal injections after surgery. Generally, drug clearance has been assumed to increase and drug effectiveness decrease in vitrectomized eyes. Most of the large clinical trials of anti-VEGF drugs were performed in nonvitrectomized eyes and do not answer how the effect of treatment with these drugs may be altered in vitrectomized eyes. Although few animal studies have compared intravitreal anti-VEGF concentrations of vitrectomized eyes with those of nonvitrectomized eyes, it is diffi cult to draw defi nite conclusions from the available data in vitrectomized human eyes. We aimed to discuss effects of vitrectomy on pharmacokinetics of anti-VEGF agents and clinical outcomes in this review.

Özet

İntravitreal anti-vasküler endotelyal büyüme faktörü (anti-VEGF) enjeksiyonları günümüzde retina sahasında en çok uygulanan tedavi yönte- midir. Klinisyenler anti-VEGF tedavisi uygulanan gözlerde pars plana vitrektomi gerektiren durumlarla karşı karşıya kalmakta ve birçok hasta- da arka segment hastalığının kronik ve rekürren doğasından dolayı intravitreal enjeksiyonlara cerrahiden sonra da devam etmek gerekmektedir. Vitrektomize gözlerde ilaç klirensinin arttığı ve etkinliğinin azaldığı genel kabul görmektedir. Anti-VEGF ilaçlarla yapılan geniş serili klinik çalışmaların çoğu vitrektomize olmayan gözlerde yapılmış olup vitrektomize gözlerde bu ilaçlarla tedavi etkinliğinin nasıl bir değişim gös- terdiği sorusuna yanıt vermezler. Vitrektomize gözlerde intravitreal anti-VEGF konsantrasyonunu vitrektomize olmayan gözlerle kıyaslayan az sayıda hayvan çalışması olsa da eldeki verilerle vitrektomize insan gözlerinde kesin yargıya varabilmek zor görünmektedir. Bu derlemede vitrektominin anti-VEGF ilaçların farmakokinetiğine ve klinik sonuçlara olan etkisini irdelemeyi amaçladık.

🔖

Cite This Article

KERİMOĞLU, H. (2018). Intravitreal Anti-VEGF Drug Injections in Vitrectomized Eyes. Retina-Vitreus, Cilt: 27 - Sayı: 4, 307–313. https://ajindex.com/articles/304880

References (12)

  1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419-31
  2. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for mac- ular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12 The CATT Research Group. Ranibizumab and Bevacizumab for Neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
  3. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal afl iber- cept for diabetic macular edema. Ophthalmology 2014;121:2247- 54 Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevaci- zumab after topical, subconjunctival, and intravitreal administrati- on in rabbits. Invest Ophthal Vis Sci 2009;50:4807-13
  4. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravit- real bevacizumab (Avastin). Ophthalmology 2007;114:855-9
  5. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravit- real ranibizumab (Lucentis).Ophthalmology 2007;114:2179-82
  6. Sinapis CI, Routsias JG, Sinapis AI, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits. Clin Ophthalmol 2001;5:697-704
  7. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-12
  8. Meyer CH, Krohne TU, Holz FG, et al. Intraocular pharmacokine- tics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877-84
  9. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-6
  10. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33 Stewart MW. What are the half-lives of ranibizumab and afl iber- cept (Trap-eyeVEGF) in human eyes? Calculation swith a mathe- matical model. Eye Reports 2011; 1:5 Park SJ, Choi Y, Mi Na Y, et al. Intraocular Pharmacokinetics of Intravitreal Afl ibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci 2016;57: 2612-7
  11. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharma- cokinetics following intravitreal injections of ranibizumab, be- vacizumab or afl ibercept in patients with neovascular AMD. Br J Ophthalmol 2014;98:1636-41
  12. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmaco- kinetics and pharmacodynamic